ArticleAnimals : an open access journal from MDPI2025
Clinical and Clinico-Pathological Observations of the Erythrocyte Sedimentation Rate in Dogs Affected by Leishmaniosis and Monitored During Antileishmanial Treatment.
Article in Animals : an open access journal from MDPI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Updated Canine Leishmaniosis Working Group recommendations for leishmaniosis in dogs: Q&A on clinical management.Parasites & vectors · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The erythrocyte sedimentation rate (ESR) is used in canine medicine in several disorders, especially to evaluate the levels of inflammation. ESR is a valid inflammatory marker in canine leishmaniosis (CanL), being markedly increased in sick dogs. This study evaluated the ESR together with several other inflammatory and immune response markers in 43 dogs affected by severe leishmaniosis, treated with antileishmanial treatment. Dogs were monitored at the beginning (T1) of treatment, in the middle (T2) of treatment, and 7-10 days after the end of the treatment (T3). The antileishmanial treatment was based on meglumine antimoniate and allopurinol for four weeks plus adding prednisolone at the anti-inflammatory dosage progressively tapered within the T2 set point. The ESR was measured and compared to immune and/or inflammatory markers (C-reactive protein, fibrinogen, ferritin, gamma-globulins, IgG). ESR levels were statistically reduced during treatment and significantly decreased at the end of the treatment. This came along with an improvement in other blood markers. This study shows the utility of ESR as a point-of-care test that can be used to monitor the response of dogs to antileishmanial treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.